Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic

Rheumatology and Therapy

Volumn 2, Issue 1, 2015, Pages 59-71

  Johnston, Stephen S ^a   McMorrow, Donna ^a   Farr, Amanda M ^a   Juneau, Paul ^a   Ogale, Sarika ^b  

^a IBM WATSON HEALTH   (United States)

^b GENENTECH INC   (United States)

Author keywords

Biologics; Persistence; Rheumatoid arthritis; Switching

Indexed keywords

EID: 85002509248     PISSN: 21986576     EISSN: 21986584     Source Type: Journal    
DOI: 10.1007/s40744-014-0006-3     Document Type: Article

References (24)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75. DOI: 10.1136/ard.2009.126532
2. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625–39. DOI: 10.1002/acr.21641
3. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174. DOI: 10.1186/ar2084
4. Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005;64:1274–9. DOI: 10.1136/ard.2004.031476
5. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387–93. DOI: 10.1136/ard.2008.105064
6. Truven Health Analytics. MarketScan Bibliography. Available at: http://marketscan.truvenhealth.com/marketscanuniversity/publications/2012%20Truven%20Health%20MarketScan%20Bibliography.pdf. Accessed June 20, 2013.
7. CPT copyright (2009) American Medical Association. All rights reserved.
8. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9. DOI: 10.1016/0895-4356(92)90133-8
9. Fowler R, Johnston SS. (Podium Presentation) Comparative performance of risk adjustment measures in a sample of commercially-insured patients under age 65—two simple measures outperform current standards. Value Health. 2010;13:A4.t. DOI: 10.1016/S1098-3015(10)72001-5
10. Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008;10:R95. DOI: 10.1186/ar2482
11. Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204. DOI: 10.1186/1471-2474-12-204
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. DOI: 10.1080/01621459.1958.10501452
13. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220.
14. Huber P. J. The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. vol. 1. Berkeley: University of California Press; 1967. pp. 221–233.
15. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817–30. DOI: 10.2307/1912934
16. Greene WH. Econometric analysis. 4th ed. Upper Saddle River: Prentice-Hall; 2000.
17. Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time to event data. 2nd ed. New York: Wiley; 2008. DOI: 10.1002/9780470258019
18. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29:664–74. DOI: 10.1007/s12325-012-0037-5
19. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30:1375–84. DOI: 10.1016/S0149-2918(08)80063-X
20. Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71:1134–42. DOI: 10.1136/annrheumdis-2011-150573
21. Markenson JA, Gibofsky A, Palmer WR, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011;38:1273–81. DOI: 10.3899/jrheum.101142
22. McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid arthritis. J Rheumatol. 2011;38:2141–9. DOI: 10.3899/jrheum.101195
23. Strand V, Williams S, Miller PSJ, et al. Discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the consortium of rheumatology researchers of North America (CORRONA) database [abstract]. EULAR Annual European Congress of Rheumatology; 12–15 June 2013; Madrid, Spain. Abstract no. OP0064.
24. Elkin E, Bergman M. J, Kamath T, et al. Reasons for discontinuation of biologic agents in rheumatoid arthritis patients. ACR/ARHP 2013 Annual Meeting. Abstract no. 1468.